The quantity and quality of tumor-infiltrating lymphocytes are key factors that forecast prognostic and therapeutic benefits in many types of cancer, such as oral squamous cell carcinoma, HER2-positive breast cancer, and epithelial ovarian cancer (Salgado et al., 2015; Hwang et al., 2019; Shaban et al., 2019; Paijens et al., 2021). This evidence concerns the gene ERBB2 and neoplasm.